EFL030
Join host Chase Hendrickson, MD, from Vanderbilt University Medical Center, as he discusses a recent JCEM article with Katie Guttenberg, MD, from University of Texas Health at Houston and Maria Fleseriu, MD, director of the NW Pituitary Center at Oregon Health & Science University. The article featured this month, by Gadelha et al, is from the July 2022 print edition of JCEM: “Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.”
Meet the Speakers
Maria Fleseriu, MD, FACE, is a professor of medicine and neurological surgery, director of the Pituitary Center, and Pituitary Fellowship Program director at Oregon Health & Science University in Portland, Ore. She has a long-standing clinical and research interest in the pathophysiology and treatment of pituitary and adrenal disorders and has been global principal investigator in many pituitary disorders clinical trials for Cushing’s, acromegaly and growth hormone deficiency. She is past president of the Pituitary Society and past chair of the Endocrine Society Guidelines Committee and the Hypopituitarism Task Force of the Endocrine Society, and serves on the Board of Directors, chairs the Physician Education Committee, and co-chaired the Consensus Cushing’s guidelines for the Pituitary Society. She has been serving on several other committees for the Endocrine Society, the Pituitary Society, and the European Society of Endocrinology. Dr Fleseriu is a frequent plenary guest speaker at national and international meetings and has received several awards, including the title of “Doctor Honors Causa” by the University of Medicine and Pharmacy “Carol Davila” and the Clinical Endocrinology Trust Award from the UK Society of Endocrinology. She is deputy editor for European Journal of Endocrinology, associate editor for Reviews of Endocrinology and Metabolism, and a member of many editorial boards, including Pituitary. She is very passionate about teaching and has been closely involved in leadership positions of educational programs sponsored by the Endocrine Society, the Pituitary Society, and patient advocacy groups to teach physicians and patients about pituitary tumors and neuroendocrine disorders. Dr. Fleseriu has authored more than 200 manuscripts in prestigious journals, including research on novel treatments, international guidelines and consensus papers for Cushing’s, acromegaly, and hypopituitarism.
Fleseriu: Disclosures potentially related to Cushing’s in the last 24 months:
• Grant Recipient to University: Recordati, Sparrow, Xeris
• Occasional Scientific Consultant: HRA Pharma, Recordati, Sparrow, Xeris
Katie Guttenberg, MD, is Associate Professor of Medicine at McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth), where she directs the endocrinology fellowship program. She received her medical degree from the Perelman School of Medicine at the University of Pennsylvania. She completed her medical residency, fellowship in endocrinology, and fellowship in medical education at the University of Pennsylvania. Dr. Guttenberg was inducted into the McGovern Medical School at UTHealth Academy of Master Educators in 2020 and received the Smythe Award for Excellence in Resident Education. Her clinical practice focuses on pituitary disorders. She currently serves on the Endocrine Society Trainee and Career Development Core Committee.
Resources
